Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You have been diagnosed with triple negative breast cancer (a type of breast cancer that tests negative for estrogen receptors, progesterone receptors, and HER2 protein) confirmed by a tissue biopsy
- Your breast cancer has spread to other parts of the body (metastatic), either as a new diagnosis or as a return of previous cancer, with at least one measurable area of spread shown on imaging scans
- You are generally well enough to carry out light activity and care for yourself (confirm with trial site)
- You have blood counts, liver function, and kidney function within acceptable ranges as confirmed by blood tests
- Your kidneys are working well enough, with a filtration rate of at least 50 mL/min/1.73m² (confirm with trial site)
- Your life expectancy is at least 3 months
- If you are a woman who could become pregnant, you have a negative pregnancy test before receiving the study scan medication
- You are willing to use contraception for at least 3 months after each dose of the study scan medication
- You have valid health insurance
- You are able and willing to attend all required study visits and follow all study procedures
- You are able to give written consent before any study procedures begin
Who may not be able to join:
- You have had another type of cancer in the last 3 years (except a common type of skin cancer called basal cell carcinoma)
- You are unable to lie still for at least one hour, or you have claustrophobia (fear of enclosed spaces)
- You have a serious non-cancer illness (such as a psychiatric, infectious, autoimmune, or metabolic condition) that could affect the study or your safety (confirm with trial site)
- You have a mental health condition that affects your ability to understand and agree to take part in the study
- You are pregnant, likely to become pregnant, or currently breastfeeding
- Your blood sugar level is too high (above 12 mmol/L)
- Your kidneys are not working well enough, with a filtration rate at or below 45 mL/min/1.73m² (confirm with trial site)
- You have a known allergy to any ingredient in the study scan medications used in this trial
- You weigh less than 48 kg (approximately 106 lbs)
- You are under legal guardianship or have had your personal freedoms restricted in certain legal ways (confirm with trial site)
- You have a condition that prevents you from understanding the trial information or giving informed consent
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: CAROLINE ROUSSEAU, MD, PhD, Institut de Cancérologie de l'Ouest (ICO)
Phone: +33 2 40 67 99 31
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess the concordance for tumour lesion detection with [68Ga]Ga-PentixaFor PET/CT and [18F]FDG PET/CT based on a lesion-by-lesion basis analysis performed at patient inclusion
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.